Pernix Therapeutics to Report Fourth Quarter and Full Year 2013 Financial Results on March 17, 2014

HOUSTON--(BUSINESS WIRE)--

Pernix Therapeutics Holdings, Inc. PTX, a specialty pharmaceutical company, today announced that it will release its fourth quarter and full year 2013 financial results before the U.S. stock market opens on Monday, March 17, 2014 and has scheduled a conference call at 9:00 a.m. EDT that day to discuss the financial results.

The conference call will feature remarks by Douglas Drysdale, Chairman of the Board, President, and Chief Executive Officer, and Tracy Clifford, Principal Accounting Officer. To participate in the conference call, please dial (877) 312-8783 (domestic) or (408) 940-3874 (international). Participants can reference the passcode 1582135. Please dial in approximately 5 minutes prior to the call.

The conference call will also be available via a live listen-only webcast and can be accessed through the Investor Relations section of the Company's website www.pernixtx.com. The passcode is 1582135. Please allow extra time prior to the call to visit the Company's website and download any software that may be needed to listen to the webcast.

A replay of the conference call will be available through March 24, 2014, at (855) 859-2056 domestic and (404) 537-3406 international. The passcode for the replay is 1582135. An online archive of the webcast will be available on the Company's website for 30 days following the call.

About Pernix Therapeutics Holdings, Inc.

Pernix Therapeutics is a specialty pharmaceutical company primarily focused on the sales, marketing, manufacturing and development of branded pharmaceutical products. The Company markets a portfolio of branded products, including: CEDAX®, an antibiotic for middle ear infections and a number of treatments for cough and cold conditions including ZUTRIPRO®, REZIRA® and VITUZ®. The Company also markets SILENOR®, a non-narcotic product for the treatment of insomnia and KHEDEZLA® for major depressive disorder. The Company promotes its branded products to physicians through its Pernix sales force and markets its generic portfolio through its wholly owned subsidiaries, Cypress Pharmaceuticals and Macoven Pharmaceuticals. The Company's wholly owned subsidiary, Pernix Manufacturing, manufactures and packages products for the pharmaceutical industry in a wide range of dosage forms. Founded in 1996, the Company is based in Houston, TX.

Additional information about Pernix is available on the Company's website located at www.pernixtx.com.